Loading…
Loading…
MTP (Midatech Pharma plc) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MIAMI--(BUSINESS WIRE)--MTP joins Real as Midwest Top Producers, adding 105 agents and 1,500 annual transactions across the Midwest.
Intesa Sanpaolo's takeover bid on smaller peer Monte dei Paschi di Siena would be the latest and biggest transformative deal for Italian banks. Here is a rundown of completed and attempted transactions that have shaken up the sector since the start of 2025.
Midatech Pharma (NASDAQ: BDRX ) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a filing with the Securities and Exchange Commission (SEC).
Midatech Pharma PLC (AIM:MTPH) fell another 13% to 3p on Wednesday, having now slashed its market valuation by half in the past five days. A day earlier, Midatech announced the proposed acquisition of Canada-listed Bioasis Technologies Inc for C$7.4mln (£4.4mln).
Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Medicines Agency had granted orphan medicinal product designation for its development programme of MTX110 for the treatment of glioma Midatech has been developing MTX110 for the treatment of recurrent glioblastoma ("rGBM") in adult patients and diffuse intrinsic pontine glioma ("DIPG") and medulloblastoma in paediatric patients.
The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for the treatment of patients with recurrent glioblastoma (rGBM). The company is planning to begin recruitment in the phase 1 study evaluating MTX110.
Midatech Pharma plc (MTP) CEO Stephen Stamp on Q2 2021 Results - Earnings Call Transcript
ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 6, 2021 / Midatech Pharma PLC (AIM:MTPH)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it will release its interim results for the six months ended 30 June 2021 at 7.00 am BST on Friday 17 September 2021. The Company will be hosting a webinar at 5.30pm BST / 12.30pm EST on Monday 20 September 2021.